Dostarlimab – March 2023

• Brand names:
  • Jemperli®
• Pharmaceutical Company:
  • GlaxoSmithKline Australia Pty Ltd
• Condition/Indication: Endometrial cancer
• Meeting Date: March 2023
• Public Summary Document (PSD) November 2022 March 2023 PBAC Meetings - (PDF 1.3MB)
• Public Summary Document (PSD) November 2022 March 2023 PBAC Meetings - (Word 447KB)

Related Public Summary Document

Dostarlimab – November 2022